Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaActive Not Recruiting
NCT06047080Phase 3Updated Jun 15, 2026
Sponsor: Hoffmann-La Roche
Large B-Cell Lymphoma
United States, Argentina, Australia, Belgium, Brazil +16 more
A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With FaricimabCompleted
NCT04597918Phase 2Updated Jun 15, 2026
Sponsor: Hoffmann-La Roche
Diabetic Macular Edema
United States, Argentina, Canada, Germany, Italy +2 more
Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal TransplantationCompleted
NCT01350882Phase 3Updated Jun 12, 2026
Sponsor: University Hospital, Tours
Humoral Rejection in Kidney Transplantation
France
COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal CancerCompleted
NCT01596790NAUpdated Jun 12, 2026
Sponsor: University Hospital, Montpellier
Metastatic Colorectal Cancer
France
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLCTerminated
NCT04984811Phase 2Updated Jun 11, 2026
Sponsor: NeoImmuneTech
Carcinoma, Non-Small-Cell Lung · Non-Small Cell Lung Cancer · Non-Small Cell Lung Carcinoma · Nonsmall Cell Lung Cancer
United States
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerCompleted
NCT03194893Phase 3Updated Jun 11, 2026
Sponsor: Hoffmann-La Roche
Neoplasms
United States, France, Hong Kong, Italy, Poland +4 more
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyActive Not Recruiting
NCT05115110Phase 2, Phase 3Updated Jun 11, 2026
Sponsor: Hoffmann-La Roche
Spinal Muscular Atrophy (SMA)
United States, Australia, Belgium, Canada, Croatia +7 more
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerActive Not Recruiting
NCT05852691Phase 2Updated Jun 11, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Australia, Brazil, Czechia +11 more
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based ChemotherapyTerminated
NCT06267001Phase 3Updated Jun 10, 2026
Sponsor: Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
Argentina, Australia, Brazil, China, Italy +6 more
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)Completed
NCT04833114Phase 3Updated Jun 10, 2026
Sponsor: GWT-TUD GmbH
Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Austria, Germany, Spain, United Kingdom
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology ProductsActive Not Recruiting
NCT05476926N/AUpdated Jun 9, 2026
Sponsor: Hoffmann-La Roche
Neovascular Age-related Macular Degeneration · Diabetic Macular Edema · Retinal Vein Occlusion · Branch Retinal Vein Occlusion
United States, Argentina, Australia, Bulgaria, Canada +24 more
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell LymphomaNot Yet Recruiting
NCT07634289Phase 2Updated Jun 8, 2026
Sponsor: Olivia Newton-John Cancer Research Institute
Relapsed /Refractory DLBCL
Australia
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive Not Recruiting
NCT04931342Phase 2Updated Jun 8, 2026
Sponsor: Hoffmann-La Roche
Ovarian Cancer
United States, Australia, Canada, Czechia, France +8 more
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural MesotheliomaRecruiting
NCT05765084Phase 1, Phase 2Updated Jun 5, 2026
Sponsor: University Hospital, Antwerp
Malignant Pleural Mesothelioma
Belgium
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus ErythematosusActive Not Recruiting
NCT05835986Phase 1Updated Jun 5, 2026
Sponsor: Hoffmann-La Roche
Systemic Lupus Erythematosus
Colombia, France, Germany, Malaysia, Mexico +8 more
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active Not Recruiting
NCT03178552Phase 2, Phase 3Updated Jun 5, 2026
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +22 more
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung CancerCompleted
NCT04619797Phase 2, Phase 3Updated Jun 3, 2026
Sponsor: Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
United States, Belgium, Brazil, Canada, China +16 more
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)Completed
NCT04513925Phase 3Updated Jun 3, 2026
Sponsor: Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
United States, Argentina, Australia, Austria, Belgium +21 more
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid TumorsTerminated
NCT04303858Phase 1Updated Jun 2, 2026
Sponsor: Hoffmann-La Roche
Solid Tumors
Belgium, Denmark, Netherlands, Poland, Spain
Benefit of Self-monitoring of Anticoagulation InstrumentCompleted
NCT00506870NAUpdated Jun 1, 2026
Sponsor: University Hospital, Bordeaux
Mechanical Prosthetic Heart Valve Implantation · Patient Self Monitoring of Oral Anticoagulent Therapy
France
A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not Yet Recruiting
NCT07618390Phase 2Updated Jun 1, 2026
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsCompleted
NCT02075840Phase 3Updated May 29, 2026
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
United States, Australia, Bosnia and Herzegovina, Brazil, Canada +24 more
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaActive Not Recruiting
NCT04077723Phase 1, Phase 2Updated May 29, 2026
Sponsor: Hoffmann-La Roche
Lymphoma, Non-Hodgkin
United States, Australia, Belgium, Canada, China +7 more
Efficacy of Faricimab in Patients With Subretinal Hyper-reflective MaterialRecruiting
NCT07403825Phase 4Updated May 28, 2026
Sponsor: Biobizkaia Health Research Institute
Macular Degeneration, Age Related
Spain
Identification of Liver Fibrosis BiomarkersRecruiting
NCT06819917N/AUpdated May 27, 2026
Sponsor: Roche Diagnostics GmbH
Non-alcoholic Fatty Liver · Non-Alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis
Denmark, Germany

Previous page Next page